24/7 Market News Snapshot 13 October, 2025 – Visionary Holdings Inc. Common Shares (NASDAQ:GV)

October 13, 2025

DENVER, Colo., 13 October, 2025 (www.247marketnews.com) – (Nasdaq:GV) are discussed in this article.
Visionary Holdings Inc. is experiencing notable market momentum, with shares currently trading at $1.747, reflecting a robust increase of approximately 14.93% since the previous session’s close at $1.520. The impressive trading volume of 6.46 million shares indicates heightened investor interest and engagement. However, technical indicators such as the Relative Strength Index (RSI) suggest potential overbought conditions, prompting caution for short-term traders. Investors should observe key support levels at $1.550 and resistance near $1.800 as they navigate future price movements.

In conjunction with its market performance, Visionary Holdings (Nasdaq:GV) has embarked on a transformative journey through its subsidiary, Visionary Holdings (Asia) Limited, by signing a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. This landmark partnership grants GV worldwide rights to advance Yike’s innovative stem cell technology, which holds promise for revolutionizing treatment options for diabetes and other regenerative medical challenges.

The collaboration aims to unlock significant breakthroughs in stem cell therapy, anti-aging biological repair, and cellular rejuvenation, with clinical trials indicating the potential for long-term remission and, in some cases, complete cures for Type 1 and Type 2 diabetes. This development addresses a pressing global health crisis affecting over 540 million adults.

GV will leverage its extensive international commercialization network to effectively launch and scale these innovative treatments worldwide, operating under a revenue-sharing model based on product sales. CEO Xiyong Hou emphasized that this agreement marks a pivotal moment for the company’s global health strategy, as it combines advanced regenerative science with robust market capabilities, setting the stage for substantial revenue growth and improved health outcomes for patients facing diabetes. Through ongoing research and development, GV and Yike remain committed to exploring clinical applications and compliance with global certification standards, positioning Visionary Holdings Inc. as a leader in the evolving medical technology landscape.

Related news for (GV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.